Jasper Therapeutics receives Nasdaq minimum bid price deficiency notice
Jasper Therapeutics received written notice from Nasdaq on June 3, 2026, that its voting common stock bid price had closed below the $1.00 per share minimum required under Nasdaq Listing Rule 5550(a)(2) for the last thirty consecutive business days. The company has been granted an initial 180-calendar-day compliance period through November 30, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for a minimum of ten consecutive business days. If compliance is not achieved by that date, the company may be eligible for an additional 180-calendar-day period if it meets other listing standards, or it may face delisting notification.
Key facts
- Notice received June 3, 2026, from Nasdaq
- Bid price closed below $1.00 per share minimum for thirty consecutive business days
- Nasdaq Listing Rule 5550(a)(2)
- Initial compliance period: 180 calendar days through November 30, 2026
- Compliance requirement: closing bid price of $1.00 or more for minimum of ten consecutive business days
- Voting common stock and public warrants continue to trade under symbols JSPR and JSPRW on Nasdaq Capital Market
- Company considering reverse stock split as one option to regain compliance
Why it matters
A failure to regain compliance by November 30, 2026, could result in delisting from Nasdaq, which would materially affect the liquidity and market access of Jasper Therapeutics' securities.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-09. Not investment advice. View the source filing on SEC.gov →